1 of 1
Story summary
- Professor Ursula Quitterer of ETH Zurich developed Compound 10 to block GRK2 aggregation in Alzheimer’s disease.
- In mouse Alzheimer models, Compound 10 stopped GRK2 aggregation, restored mitochondria, lowered amyloid-beta, and kept neurons alive.
- Treated mice survived longer, showed delayed neurodegeneration, improved heart function, and exhibited less greying fur.
- The team patented Compound 10 and is seeking partners for safety testing and clinical trials, offering a mechanism unlike current Alzheimer drugs.
